News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
The move will add new global talent to Cytel’s Strategic Consulting group
The Bulk Drug Park is expected to attract investment of around Rs. 10,000 crore and provide employment to more than 20,000 people
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Subscribe To Our Newsletter & Stay Updated
